Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Neoplasms × ruxolitinib × Clear all

Phase

Phase 1 4 Phase 3 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Myeloproliferative Disorders 5 Primary Myelofibrosis 4 Polycythemia Vera 4 Pancreatic Neoplasms 2 Hematologic Diseases 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pathologic Complete Response 1 Neoplasms 1 Lymphoma, Follicular 1 Bone Marrow Diseases 1

Interventions

Paclitaxel 19 Dexamethasone 16 Bevacizumab 16 Oxaliplatin 14 Docetaxel 14 Cyclophosphamide 12 Capecitabine 12 Gemcitabine 11 Sorafenib 10 Leucovorin 10 Fluorouracil 10 Carboplatin 10 Epoetin Alfa 9 pembrolizumab 8 Pemetrexed 8 Fentanyl 8 venetoclax 7 atezolizumab 7 Rivaroxaban 7 Prednisone 7 Drug Therapy 7 Doxorubicin 7 Anastrozole 7 Rituximab 6 Ondansetron 6 Morphine 6 Irinotecan 6 Denosumab 6 Cisplatin 6 Tranexamic Acid 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04472598 2025-02-21

TRANSFORM-1

AbbVie

Phase 3 Completed

Neoplasms, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡